Navigation Links
Tools for Proteomic Science II

f glycosylated and nonglycosylated proteins in a single lane is also possible.

Labeling and detection

With the nonradioactive coupling reagents and the Protein Labeling Kits, Roche Applied Science provides a simple and rapid method for the labeling of proteins with alkaline phoshatase, biotin, digoxigenin, fluorescein, or peroxidase. Streptavidin and antibody conjugates recognize biotin or digoxigenin and fluorescein, and allow the convenient detection of labeled proteins.

Epitope tagging

Epitope tagging eliminates the laborious and time-consuming task of producing a new antibody every time a protein is studied. Our anti-Tag antibodies simplify the detection, characterization, and purification of proteins. They are also available in conjugated forms, and recognize commonly used epitope sequences, such as the influenza hemagglutinin protein (HA), human c-myc protein, six histidine residues (His6), and others. The epitope sequences can be easily inserted at the desired position within the protein amino-acid sequence using recombinant DNA techniques. In particular, our anti-HA antibody (clone 3F10) represents a powerful antibody for detection and purification due to its high affinity.

Western blotting

Detect your protein by colorimetric or chemiluminescence methods: The detection of proteins using chemiluminescence has become the method of choice, with peroxidase and luminol reagents being the most popular chemiluminescence system for protein detection. You can save sample material by using our sensitive Lumi-LightPLUS Western blotting substrates, kits, and polyvinylidene difluoride (PVDF) membranes. The Lumi-LightPLUS substrate enables multiple exposures due to the high stability of the s
'"/>

Source:


Page: All 1 2 3 4

Related biology technology :

1. Tools for Detecting MSH2 Expression in Chinese Hamster Ovary Cells
2. Gene Expression Arrays: Highly Sensitive Detection of Expression Patterns with Improved Tools for Target Amplification
3. New Tools for Small RNA Analysis
4. Research Tools for Analysis of ZAP-70
5. SNPs Powerful Tools for Association Studies
6. New Tools for Making and Processing Protein Microarrays.
7. Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C
8. Fully Automated Nano-Electrospray Coupled with a Finnigan LCQ Deca XP Plus for Sub-fmol Proteomic Analysis
9. Protein Depletion for Plasma and Serum Proteomic Analysis
10. Advantages of Roche Applied Science amplification products
11. Exploiting the Life Science Data Explosion to Speed New Drug Discovery

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Tools for Proteomic Science

(Date:11/5/2009)... GAITHERSBURG, Md., Nov. 5 /PRNewswire-FirstCall/ ...ts financial results for the third quarter ended S...3.6 million ($0.04 per share) for the three months...f $6.8 million ($0.08 per share) in the comparable...ber 30, 2009, GenVec,s net loss was $14.1 million ...
(Date:11/5/2009)... PARSIPPANY, N.J., Nov. 5 DSM Phar...de a manufacturing alliance with Galenix, Saint Je...d commercial scale manufacturing partner for Galen...M and Galenix will collaborate on business develop...ery technologies, based on the strength of Galenix...
(Date:11/5/2009)... RANCHO CORDOVA, Calif., Nov. 5 /PRNewswire-FirstC...ading supplier of innovative products for processi...sults for the first quarter of fiscal 2010. ,, ...any reported revenues of $5.2 million, a 15 percen...rst quarter a year ago. The Company said the key c...
(Date:11/5/2009)... OMAHA, Neb., Nov. 5 Tra...nnounced financial results for the quarter ended S... are presented in the tables that follow. ,, T...t loss of $366,000 or $0.01 per share for the thir...9,000 or $0.01 per share for the third quarter of ...
Breaking Biology Technology:GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7
...2 Nektar,Therapeutics (Nasdaq: NKTR ) announced ...nsition from a drug delivery service provider to a...estructuring will,streamline the company, consolid...aking and execution within the business units., "... development company,and these changes are a natur...
...formance in 2007 and Notes Achievements over 4-ye... BioSciences, Preparing for Cha...ing-Plough,Corporation (NYSE: SGP ) today reporte...d full year, and commented on its ongoing integrat...cquired in November 2007 and,includes the Organon ...
...nternational,Corporation (Nasdaq: PRXL ) announce... 2-for-1 split of its Common Stock, which will be ...ers of PAREXEL,s Common Stock will receive one add...mmon Stock held on the record date of,February 22,...n or about,March 3, 2008 by PAREXEL,s transfer age...
Other Biology Technology:Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization 2Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization 3Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 2Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 3Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 4Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 5Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 6Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 7Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 8Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 9Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 10Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 11Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 12Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 13Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 14Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 15Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 16Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 17Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 18Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 19Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 20Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 21Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 22Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 23Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 24Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 25Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 26Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 27Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 28PAREXEL International Announces 2-For-1 Stock Split 2PAREXEL International Announces 2-For-1 Stock Split 3
(Date:11/4/2009)... 2009 Childhood obesity in the United States is r...ourth of advertising on daytime and prime time tel...ing questions about the role television plays in o...the Journal of Nutrition Education and Behavior ...ght be a large contributor to the problem. , Res...
(Date:11/4/2009)...hat deciphered the DNA codes, or genomes, of the f...joined The Genome 10K Project, an international ef...ences on 10,000 species of animals for conducting ...not be achieved. , Participating in The Genome 1...Nov. 5, 2009 issue of the Journal of Heredity , a...
(Date:11/4/2009)..., Oct. 19 Spectros, developer and ...ging devices which shed light on life-threatening ...sive distribution deals for both its T-Stat® ...red include Australia, New Zealand, The Netherlan..., France, Spain, Portugal, Poland, Greece, Turkey,...
Breaking Biology News(10 mins):TV bombards children with commercials for high-fat and high-sugar foods 2TV bombards children with commercials for high-fat and high-sugar foods 3Singapore scientists join international study of 10,000 vertebrates' genomes 2Spectros Signs New International Distribution Deals 2Donor Sperm Providers Form New Non Profit 59569 1Oaks Development Group Launches Physician Incubator Space in Palm Coast Medical Office Building 59566 1Oaks Development Group Launches Physician Incubator Space in Palm Coast Medical Office Building 59566 2MedImmune Highlights Inflammatory Disease Portfolio at 73rd Annual Meeting of the American College of Rheumatology 14494 1MedImmune Highlights Inflammatory Disease Portfolio at 73rd Annual Meeting of the American College of Rheumatology 14494 2MedImmune Highlights Inflammatory Disease Portfolio at 73rd Annual Meeting of the American College of Rheumatology 14494 3
...reasing amounts of ice mass have been lost from We... past ten years, according to research from the Un... in Nature Geoscience. , Meanwhile the ice mass ...either loss nor accumulation over the past decade.... Bristol and colleagues estimated the flux of ice ...
...N ARBOR, Mich.---Common genetic variants linked to... new study shows. , The international study was c...ic Health. The journal Nature Genetics will publis...onfirms observations by health professionals of a ...risk of osteoarthritis, the most common form of ar...
...tudies involving more than 35,000 people and a sur...al team supported in part by the National Institut...genetic variants recently linked to osteoarthritis...indings were released today in the advance online ...e variants most strongly associated with height in...
Other Biology News:Antarctic ice loss 2Study suggests genetic connection between short stature and arthritis 2Researchers uncover new piece to the puzzle of human height 2Researchers uncover new piece to the puzzle of human height 3Researchers uncover new piece to the puzzle of human height 4
...tion. Cleaves a-(1-3)- and a(1-6)-linked, non-r...tes and glycoproteins. It is particularly efficien... where the pH must be neutral or above, for exampl...will hydrolyze 1 mole of p-nitrophenyl a-D-galacto...
ABI3100 Adapter for ABgene from ABgene
...2-Naphthoyl-VF-CHO White lyophilized solid. PROT...ermeable, reversible inhibitor of γ-secretas...40 (ED 50 = 2.6 μM) and Aβ x-42 (ED 50 ...ith the Amyloid Precursor Protein Swedish mutants....
Acl I (Psp1406 I) from New England Biolabs
Biology Products: